Detection of Tumor-Associated Membrane Receptors on Extracellular Vesicles from Non-Small Cell Lung Cancer Patients...

Area of Science:

• Biomarkers and Diagnostics
• Oncology
• Molecular Biology

Background:

• Precision medicine for non-small-cell lung cancer (NSCLC) has improved survival but faces challenges in longitudinal treatment monitoring due to tumor heterogeneity and difficult rebiopsies.
• Liquid biopsies, including circulating tumor DNA and small extracellular vesicles (sEVs), offer a promising alternative for noninvasive monitoring.
• Tumor-associated membrane receptors like EGFR, HER2, and IGF-1R are key targets, but their expression can change during treatment, necessitating dynamic monitoring.

Purpose of the Study:

• To develop and validate an immuno-PCR (IPCR) assay for detecting tumor-associated membrane receptors (EGFR, HER2, IGF-1R) on CD9-positive sEVs.
• To assess the utility of this IPCR method for longitudinal monitoring of NSCLC treatment response and resistance.
• To evaluate the potential of sEVs as a noninvasive liquid biopsy tool for NSCLC patient management.

Main Methods:

• Development of an IPCR assay using DNA conjugates of antibody mimetics and affibodies for detecting EGFR, HER2, and IGF-1R.
• Application of the IPCR method to CD9-positive sEVs purified from NSCLC cell cultures and pleural effusion (PE) fluid from NSCLC patients.
• Validation of EGFR detection in sEVs from cells treated with anti-EGFR siRNA and comparison of EGFR levels in PE samples from different patient groups.

Main Results:

• The IPCR method successfully detected reductions in EGFR expression on sEVs from NSCLC cells treated with anti-EGFR siRNA.
• Protein profiling of sEVs from NSCLC patient PE samples demonstrated the capacity to monitor EGFR, HER2, and IGF-1R levels.
• Significantly higher EGFR levels were detected in sEVs from PE of an EGFR-driven NSCLC patient compared to non-EGFR-driven or benign lung disease samples.

Conclusions:

• An IPCR-based diagnostic method for detecting tumor markers on sEVs in liquid biopsies has been successfully developed.
• This method shows potential for noninvasive longitudinal treatment monitoring in cancer patients, aiding in the detection of resistance mechanisms.
• The study highlights the utility of sEVs and IPCR for advancing non-small-cell lung cancer diagnostics and personalized treatment strategies.